Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 12, 2013; 80 (7 Supplement) March 18,2013

Biopsy-Proven Multifocal Necrotizing Leukoencephalopathy Following Systemic Methotrexate Monotherapy for CNS Metastasis of Non-Hodgkin Lymphoma (P01.107)

Mohammed ElHag, Mark Cohen, David Bardentstein, David Peerboom, Peter Cole, Andrew Sloan, Lisa Rogers
First published February 8, 2016,
Mohammed ElHag
1Pathology University Hospitals of Cleveland Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Cohen
2Pathology University Hospitals of Cleveland Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Bardentstein
3Ophthalmology University Hospitals of Cleveland Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Peerboom
4Neurology Cleveland Clinic Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Cole
5 Childrens Hospital at Montefiore Bronx NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Sloan
6Neurosurgery University Hospitals of Cleveland Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Rogers
7Neurology University Hospitals of Cleveland Cleveland OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Biopsy-Proven Multifocal Necrotizing Leukoencephalopathy Following Systemic Methotrexate Monotherapy for CNS Metastasis of Non-Hodgkin Lymphoma (P01.107)
Mohammed ElHag, Mark Cohen, David Bardentstein, David Peerboom, Peter Cole, Andrew Sloan, Lisa Rogers
Neurology Feb 2013, 80 (7 Supplement) P01.107;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To characterize the clinical, MRI, and pathology findings in an unusual case of multifocal necrotizing leukoencephalopathy (MNL) developing after systemic methotrexate (MTX).

BACKGROUND: There is a variety of neurotoxicities associated with systemic or intrathecal administration of MTX. MNL typically occurs after combined MTX and cranial RT (Rubinstein et al 1975) and is typically irreversible and fatal.

DESIGN/METHODS: Case Report.

RESULTS: At age 36, the patient was treated with CHOP-R for systemic Non-Hodgkin lymphoma. Two months after treatment he was diagnosed with ocular and leptomeningeal lymphoma and received high-dose (8gm/M2) intravenous MTX. He developed progressive vision loss and left limb weakness during treatment and immediately after the 5th dose became somnolent and awoke with severe left limb paresis. He was referred for further evaluation. Exam revelaed bilateral optic atrophy, mild left facial weakness, severe left limb weakness, confusion and agitation. Review of serial brain MRIs showed development of multifocal T2/FLAIR hyperintensities in cerebral hemisphere white matter, basal ganglia and cerebellum, mild contrast enhancement, without restricted diffusion. Homozygosity for MTHFR C677T was identified in blood. Cerebellar lesion biopsy revealed vacuolization and sparse axonal swelling, consistent with myelinolysis, and lipid-laden macrophages. CSF metabolites consistent with MTX toxicity were elevated, but must be interpreted with caution because CSF was contaminated by RBC. He was treated with high dose folic acid and memantine. Six months later, blindness persists but his mentation and limb weakness are significantly improved.

CONCLUSIONS: MNL occurs almost exclusively following combined intrathecal or systemic MTX and brain RT. This case adds to the repertoire of neurotoxicity of systemic MTX monotherapy. The pathology findings are identical to MNL after combination treatment except for less evidence of axonal damage. It is speculative if his clinical improvement is attributable to therapy with folic acid and memantine or to a milder degree of tissue injury than is typical of MNL.

Disclosure: Dr. ElHag has nothing to disclose. Dr. Cohen has nothing to disclose. Dr. Bardentstein has nothing to disclose. Dr. Peerboom has nothing to disclose. Dr. Cole has nothing to disclose. Dr. Sloan has nothing to disclose. Dr. Rogers has received personal compensation for activities with Sigma Tau Pharmaceuticals as a speaker.

Monday, March 18 2013, 2:00 pm-6:30 pm

  • Copyright © 2013 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (8)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise